Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | TYMP | P19971 | 1/20 | 0.33 |
| ▸ | STAT3 | P40763 | 1/20 | 0.33 |
| ▸ | CDK4 | P11802 | 1/20 | 0.32 |
| ▸ | CCND1 | P24385 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3391908 | 0.77 | ALDH1A1 (0.32) | LMNAHPGDALDH1A1L3MBTL1DAO | |
| SCHEMBL172127 | 0.75 | ALDH1A1 (0.58) | KMT2APOLBLMNAHPGDTSHR | |
| SCHEMBL718210 | 0.71 | NPSR1 (0.52) | KMT2AALDH1A1L3MBTL1TYMPCDK4 | |
| SCHEMBL22161698 | 0.70 | ALDH1A1 (0.34) | ALDH1A1KDM4E | |
| SCHEMBL31087180 | 0.70 | KDM4E (0.55) | KMT2APOLBLMNATSHRALDH1A1 | |
| SCHEMBL9616337 | 0.68 | L3MBTL1 (0.54) | KMT2APOLBLMNAHPGDTSHR | |
| SCHEMBL9879120 | 0.68 | HTT (0.63) | KMT2ALMNAHPGDTSHRALDH1A1 | |
| SCHEMBL18701511 | 0.68 | L3MBTL1 (0.44) | KMT2APOLBLMNAHPGDTSHR | |
| SCHEMBL19346601 | 0.67 | PARP1 (0.33) | CDK4CCND1PARP1 | |
| SCHEMBL14636999 | 0.67 | KMT2A (0.41) | KMT2APOLBLMNAHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240307394-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR D AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2024-09-19 | — | — | US | disclosed |
| EP-1911754-B1 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2013-10-09 | — | — | EP | disclosed |
| US-7790736-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-07 | — | — | US | disclosed |
| US-7723344-B2 | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7579357-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-25 | — | — | US | disclosed |
| US-7470700-B2 | Such as 2-[2-(3-Amino-piperidin-1-yl)4-oxo-4H-quinazolin-3-ylmethyl]-benzonitrile; type 2 diabetes mellitus, diabetic dislipidemia, impaired glucose tolerance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-30 | — | — | US | disclosed |
| EP-1911754-A1 | Dipeptidyl peptidase inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
| EP-1506967-B1 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2007-11-21 | — | — | EP | disclosed |
| CN-1867560-A | 4-pyrimidone derivatives and their use as peptidylpeptidase inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2006-11-22 | — | — | CN | disclosed |
| US-20050075330-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-04-07 | — | — | US | disclosed |
| US-20050070531-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20050070535-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20050070706-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20050070530-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20050065148-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-24 | — | — | US | disclosed |
| WO-2005016911-A1 | 4-PYRIMIDONE DERIVATIVES AND THEIR USE AS PEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-24 | — | — | WO | disclosed |
| EP-1506967-A1 | Dipeptidyl peptidase inhibitors | Syrrx, Inc. (US) | 2005-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070535-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP7 | KMT2A 4029/4885POLB 2517/4885LMNA 4162/4885 |
| US-20050070531-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP7 | KMT2A 4029/4885POLB 2517/4885LMNA 4162/4885 |
| US-20240307394-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR D AND RELATED PRODUCTS AND METHODS | MRGPRX1, MRGPRX4, MRGPRX2 | KMT2A 4353/4885POLB 4859/4885LMNA 3977/4885 |
| US-20050065148-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP7 | KMT2A 4029/4885POLB 2517/4885LMNA 4162/4885 |
| US-20050075330-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP7 | KMT2A 4029/4885POLB 2517/4885LMNA 4162/4885 |
| US-20050070706-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP7 | KMT2A 4029/4885POLB 2517/4885LMNA 4162/4885 |
| US-20050070530-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP7 | KMT2A 4029/4885POLB 2517/4885LMNA 4162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.